Simulations Plus Inc (SLP) 8.85 $SLP Simulations Plus

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Simulations Plus Inc (SLP) 8.85 $SLP

Simulations Plus Releases PKPlus(TM) Version 1.0
BusinessWire - Thu Aug 25, 7:30AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that it has released version 1.0 of PKPlus, its next-generation software for analysis of preclinical and clinical trial data.
SLP: 8.85 (+0.23)

Simulations Plus Announces Quarterly Cash Dividend of $0.05 Per Share
BusinessWire - Mon Aug 01, 7:30AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.05 per share to its shareholders. This cash dividend will be distributed on Thursday, August 18, 2016, to shareholders of record as of Thursday, August 11, 2016.
SLP: 8.85 (+0.23)

Simulations Plus Releases ADMET Predictor(TM) Version 8.0
BusinessWire - Mon Aug 01, 7:30AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that it has released Version 8.0 of its best-in-class ADMET Predictor(TM) molecular property prediction software.
SLP: 8.85 (+0.23)

Simulations Plus Reports Preliminary Revenues for Third Quarter FY2016
BusinessWire - Tue Jun 07, 7:30AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for the third quarter of its fiscal year 2016, the period ended May 31, 2016 (3QFY16).
SLP: 8.85 (+0.23)

Simulations Plus to Present at LD Micro Invitational on June 7, 2016
BusinessWire - Thu Jun 02, 7:30AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all phases of pharmaceutical discovery and development, announced that Walt Woltosz, chief executive officer, will present at the 6th Annual LD Micro Invitational investor conference on Tuesday, June 7, 2016, at 11:30 a.m. PT. The conference will be held June 7-9, 2016, at the Luxe Sunset Bel Air Hotel in Los Angeles.
SLP: 8.85 (+0.23)

Simulations Plus (SLP): Moving Average Crossover Alert
Zacks Equity Research - Zacks Investment Research - Mon May 09, 9:12AM CDT
Simulations Plus, Inc. (SLP) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
SLP: 8.85 (+0.23)

Simulations Plus Releases DDDPlus Version 5.0
BusinessWire - Thu Apr 14, 7:30AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that it has released Version 5.0 of its DDDPlus(TM) in vitro dissolution experiment simulation software.
SLP: 8.85 (+0.23)

Simulations Plus posts 2Q profit
Automated Insights - Wed Apr 13, 3:06PM CDT
LANCASTER, Calif. (AP) _ Simulations Plus Inc. (SLP) on Wednesday reported fiscal second-quarter profit of $1.1 million.
SLP: 8.85 (+0.23)

Simulations Plus Reports Second Quarter FY2016 Financial Results
BusinessWire - Wed Apr 13, 3:01PM CDT
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all phases of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its second quarter of fiscal year 2016, the period ended February 29, 2016 (2QFY16).
SLP: 8.85 (+0.23)

Simulations Plus (SLP): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 7:37AM CST
Simulations Plus is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective
SLP: 8.85 (+0.23)

Shares of SLP Up 17.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 01, 5:21PM CST
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on December 29th, 2015 at $9.62. In approximately 1 month, Simulations Plus has returned 17.42% as of today's recent price of $11.29.
SLP: 8.85 (+0.23)

Simulations Plus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
BusinessWire - Tue Jan 26, 7:30AM CST
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that Walt Woltosz, Chairman and Chief Executive Officer, will provide a company overview at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on Thursday, February 11, 2016, at 8:30 a.m. EST. The conference will be held at the Convene Conference Center at 730 Third Avenue in New York City. Simulations Plus management will be available during the day for one-on-one meetings.
SLP: 8.85 (+0.23)

Uptrend Call Working As Simulations Plus Stock Rises 17.6% (SLP)
Comtex SmarTrend(R) - Mon Jan 25, 12:02PM CST
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on December 29th, 2015 at $9.62. In approximately 4 weeks, Simulations Plus has returned 17.63% as of today's recent price of $11.31.
SLP: 8.85 (+0.23)

Simulations Plus Reports First Quarter FY2016 Financial Results
BusinessWire - Thu Jan 14, 3:01PM CST
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all phases of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its first quarter of fiscal year 2016, the period ended November 30, 2015 (1QFY16).
SLP: 8.85 (+0.23)

New Information Reveals Opportunity in Volatility - Featured Research on Simulations Plus, Olympic Steel, Unity Bancorp, and Shore Bancshares
ACCESSWIRE - Mon Jan 11, 7:20AM CST
NEW YORK, NY / ACCESSWIRE / January 11, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Simulations Plus Inc. (NASDAQ: SLP), Olympic Steel Inc. (NASDAQ: ZEUS), Unity Bancorp Inc. (NASDAQ: UNTY) and Shore Bancshares Inc. (NASDAQ: SHBI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
SLP: 8.85 (+0.23), SHBI: 11.58 (-0.05), ZEUS: 20.25 (+0.92), UNTY: 12.94 (-0.05)

Simulations Plus Sets Date for 1st Quarter 2016 Earnings Release and Conference Call
BusinessWire - Fri Jan 08, 12:42PM CST
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of software and consulting services for pharmaceutical R&D and environmental toxicology, announced that it expects to file its quarterly report on Form 10-Q for the first quarter of its 2016 fiscal year, ending November 30, 2015, with the U.S. Securities and Exchange Commission on Thursday, January 14, 2016. Dr. Ted Grasela, president, and Walt Woltosz, chairman and CEO, will host a conference call to discuss the Company's performance on January 14, 2016, at 1:15 p.m. PST / 4:15 p.m. EST.
SLP: 8.85 (+0.23)

Simulations Plus to Present at Two Upcoming Investor Conferences
BusinessWire - Tue Nov 24, 7:30AM CST
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for pharmaceutical discovery and development, today announced that John DiBella ,Vice President of Marketing and Sales, will present at the LD Micro Conference at 9:00 a.m. PST, Track 5, on Wednesday, December 2, 2015. The conference will be held December 1-3, 2015 at the Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard in Los Angeles. The Company's group presentation will be available for the public to access at http://wsw.com/webcast/ldmicro9/slp. This webcast will be archived for 90 days following the live presentation. Simulations Plus management will be available during the day on Dec. 2, for one-on-one meetings. Please contact LD Micro to schedule a meeting.
SLP: 8.85 (+0.23)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 387

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 544

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 109

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 411

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 174

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading